Organization
West China Hospital of Sichuan University
5 abstracts
Abstract
Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.Org: Sun Yat-sen University Cancer Center, Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Jilin Cancer Hospital, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine,
Abstract
Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin.Org: Fudan University Shanghai Cancer Center, Cancer Institute of Jiangsu Province, Shanghai Medical College, Fudan University, The Fourth Hospital of Hebei Medical University, The First Hospital of Jilin University, Changchun, Jilin Province, China,
Abstract
A phase 2 study of HLX208, a BRAFV600E inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harboring BRAFV600E mutation.Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, West China Hospital of Sichuan University, Zhongshan Hospital of Fudan University, Shanghai, China, Huashan Hospital Fudan University, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China,
Abstract
Exploring the most appropriate primary endpoint of immune checkpoint inhibitors for previously treated advanced solid cancers.Org: Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, University of Electronic Science and Technology of China, Sichuan Cancer Hospital & Institute, Sichuan, West China Hospital of Sichuan University, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Clinical outcomes of patients with metastatic breast cancer treated with eribulin: A real-world evidence study from China.Org: West China Hospital, Sichuan University, Breast Disease Center, West China Hospital, Sichuan University, West China Hospital of Sichuan University,